Literature DB >> 29970493

Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?

Jennifer R Brown1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29970493      PMCID: PMC6029529          DOI: 10.3324/haematol.2018.196014

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

2.  Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Authors:  Asher Chanan-Khan; Paula Cramer; Fatih Demirkan; Graeme Fraser; Rodrigo Santucci Silva; Sebastian Grosicki; Aleksander Pristupa; Ann Janssens; Jiri Mayer; Nancy L Bartlett; Marie-Sarah Dilhuydy; Halyna Pylypenko; Javier Loscertales; Abraham Avigdor; Simon Rule; Diego Villa; Olga Samoilova; Panagiots Panagiotidis; Andre Goy; Anthony Mato; Miguel A Pavlovsky; Claes Karlsson; Michelle Mahler; Mariya Salman; Steven Sun; Charles Phelps; Sriram Balasubramanian; Angela Howes; Michael Hallek
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

3.  Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Max J Gordon; Michael Churnetski; Hamood Alqahtani; Xavier Rivera; Adam Kittai; Stephen M Amrock; Spencer James; Sheila Hoff; Sudhir Manda; Stephen E Spurgeon; Michael Choi; Jonathon B Cohen; Daniel Persky; Alexey V Danilov
Journal:  Cancer       Date:  2018-05-24       Impact factor: 6.860

4.  Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.

Authors:  Luc-Matthieu Fornecker; Thérèse Aurran-Schleinitz; Anne-Sophie Michallet; Bruno Cazin; Romain Guieze; Marie-Sarah Dilhuydy; Jean-Marc Zini; Cécile Tomowiak; Stéphane Lepretre; Florence Cymbalista; Annie Brion; Pierre Feugier; Alain Delmer; Véronique Leblond; Loïc Ysebaert
Journal:  Am J Hematol       Date:  2015-04-01       Impact factor: 10.047

5.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

6.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Authors:  Susan O'Brien; Richard R Furman; Steven Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff Sharman; William Wierda; Jeffrey Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Ying Luan; Danelle F James; Alvina D Chu; John C Byrd
Journal:  Blood       Date:  2018-02-02       Impact factor: 25.476

7.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

8.  Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Authors:  J R Brown; P Hillmen; S O'Brien; J C Barrientos; N M Reddy; S E Coutre; C S Tam; S P Mulligan; U Jaeger; P M Barr; R R Furman; T J Kipps; F Cymbalista; P Thornton; F Caligaris-Cappio; J Delgado; M Montillo; S DeVos; C Moreno; J M Pagel; T Munir; J A Burger; D Chung; J Lin; L Gau; B Chang; G Cole; E Hsu; D F James; J C Byrd
Journal:  Leukemia       Date:  2017-06-08       Impact factor: 11.528

9.  Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Andrew D Zelenetz; Jacqueline C Barrientos; Jennifer R Brown; Bertrand Coiffier; Julio Delgado; Miklós Egyed; Paolo Ghia; Árpád Illés; Wojciech Jurczak; Paula Marlton; Marco Montillo; Franck Morschhauser; Alexander S Pristupa; Tadeusz Robak; Jeff P Sharman; David Simpson; Lukáš Smolej; Eugen Tausch; Adeboye H Adewoye; Lyndah K Dreiling; Yeonhee Kim; Stephan Stilgenbauer; Peter Hillmen
Journal:  Lancet Oncol       Date:  2017-01-28       Impact factor: 41.316

10.  Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Authors:  Anthony R Mato; Chadhi Nabhan; Meghan C Thompson; Nicole Lamanna; Danielle M Brander; Brian Hill; Christina Howlett; Alan Skarbnik; Bruce D Cheson; Clive Zent; Jeffrey Pu; Pavel Kiselev; Andre Goy; David Claxton; Krista Isaac; Kaitlin H Kennard; Colleen Timlin; Daniel Landsburg; Allison Winter; Sunita D Nasta; Spencer H Bachow; Stephen J Schuster; Colleen Dorsey; Jakub Svoboda; Paul Barr; Chaitra S Ujjani
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.